Listen to this exclusive interview with Dirk Arnold from Klinik für Tumorbiologie (Freiburg, Germany) about current treatment options for rectal cancer, how we can define a strategy for oligometastic rectal cancer and his hopes for the future of this field.
Browsing: Disease Area > Colorectal
A novel global study has set a risk-based standard in order to personalize chemotherapy for colon cancer following surgery.
A novel genetic test may help identify individuals at high-risk of anal cancer.
Editor, Jade Parker recently spoke with David Adams, Wellcome Trust Sanger Institute (Cambridge, UK) about utilizing DNA sequencing of patients and genetic screens in human cells and mice to identify cancer genes and genetic interactions.
Discover more about the molecular profiles of brain metastases from colorectal cancer and corresponding primary tumors with a focus on KRAS, NRAS, BRAF and PIK3CA in this research article from Future Oncology.
In this systematic review from Pharmacogenomics find out about the influence pharmacogenetics and ethnicity can have on oxaliplatin therapy for colorectal cancer.
In this commentary article from Colorectal Cancer the authors highlight the importance of considering BRAF-mutations when formulating treatment strategies for metastatic colorectal cancer.
What are the current immunotherapeutic options for colorectal cancer? Find out in this review article from Immunotherapy.
Researchers discover that short course pre-operative radiotherapy combined with delayed surgery is an effective treatment with few side effects for patients with rectal cancer.
In this editorial from Epigenomics the authors explore the possibility of utilizing miR-625-3p in the treatment of colorectal cancer.